This site is intended for health professionals only

GSK acquires Sirtris


GlaxoSmithKline (GSK) announced today that it has completed its acquisition of Sirtris Pharmaceuticals Inc for approximately $720 million (EUR465 million) through a cash tender offer of $22.50 (EUR14.50) per share.

Through the acquisition of Sirtris, GSK has significantly enhanced its metabolic, neurology, immunology and inflammation research efforts by establishing a presence in the field of sirtuins, a recently discovered class of enzymes that is believed to be involved in the ageing process.

Sirtris will become part of GSK’s Drug Discovery organisation, while continuing to operate from laboratories in Cambridge, Massachusetts as an autonomous drug discovery unit.


Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine